RxDoctor Payments DataLook up a doctor →

Ernesto Gomez, MD

Obstetrics & Gynecology · Mesa, AZNPI 1386685055

Payments from drug & device makers

$1,507,199in general payments, 2019–2025

Across 632 payments — averaging $2384.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$742K
  • Exeltis, USA Inc.$297K
  • Mylan Inc.$274K
  • Sumitomo Pharma America, Inc.$119K
  • Organon$45K
  • Myovant Sciences Inc.$21K
  • plus $8K from 22 others

What the payments were for

  • Speaking & faculty fees$121,50084%
  • Travel & lodging$16,92312%
  • Food & beverage$6,7035%
  • Education$1380%
  • Gifts$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,507,199 in reported general payments places this provider in the 95th percentile of 757 obstetrics & gynecology providers in Arizona.

See all obstetrics & gynecology providers in Arizona

Medicare billing

Part B allowed, 2024
$1,135,247
Medicare patients
578
Services billed
23,810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron51$38,734
Estradiol234$12,200
Estradiol (Twice Weekly)Estradiol73$8,046
ProgesteroneProgesterone, Micronized104$4,211
Liothyronine Sodium62$2,601
Estradiol (Once Weekly)Estradiol23$1,179
Raloxifene Hcl26$1,009
Testosterone Cypionate63$581
Spironolactone30$572
Clobetasol Propionate16$532
Oxybutynin Chloride ErOxybutynin Chloride14$479
Levothyroxine Sodium50$394
Hydroxyzine Hcl14$217
Ketoconazole16$188
Fluconazole18$174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$164$38,73451 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 757 obstetrics & gynecology providers in Arizona.

Other obstetrics & gynecology in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →